All
FDA Grants Priority Review to Adcetris Consolidation in Hodgkin Lymphoma
April 22nd 2015The FDA has granted a priority review to the antibody-drug conjugate Adcetris as a consolidation therapy following autologous stem cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression.
Xalkori Granted Breakthrough Designation for ROS1-Positive Lung Cancer
April 21st 2015The Food and Drug Administration has granted a breakthrough therapy designation to Xalkori (crizotinib) as a potential treatment for patients with ROS1-positive non–small cell lung cancer, based on phase 1 findings published in the New England Journal of Medicine.
Long-Term Aspirin Use Decreases Risk of Gastrointestinal Cancers, Especially Colorectal
April 20th 2015A recent study joins a body of evidence suggesting that long-term, regular aspirin use is associated with a reduced risk for cancer, with the most dramatic reduction being seen in colorectal cancer incidence.
Early Phase Study Shows MM-302 Has Activity in Heavily-Pretreated HER2-Positive Breast Cancer
April 20th 2015MM-302, a novel antibody-drug conjugate that specifically targets cancer cells overexpressing the HER2 receptor, showed signs of clinical activity in heavily pretreated patients with metastatic, HER2-positive breast cancer.